Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744785 | 0.78 | L3MBTL1 (0.70) | MAPK1L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL26983350 | 0.78 | LMNA (0.52) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15759044 | 0.77 | KMT2A (0.55) | MAPK1L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3466407 | 0.76 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TDP1POLB | |
| SCHEMBL357927 | 0.74 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL29467280 | 0.73 | HSD11B1 (0.47) | MAPK1L3MBTL1KMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5013604 | 0.72 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3121516 | 0.72 | HDAC3 (0.41) | KMT2AMEN1ALDH1A1SMN1; SMN2NNMT | |
| SCHEMBL18537752 | 0.72 | CA2 (0.55) | L3MBTL1SMN1; SMN2NNMT | |
| SCHEMBL3126246 | 0.72 | NNMT (0.47) | L3MBTL1SMN1; SMN2NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | MAPK1 973/4885L3MBTL1 4281/4885KMT2A 2845/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | MAPK1 410/4885L3MBTL1 4336/4885KMT2A 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.